Holen Sie sich die Stockscreener-App
17.70
0.74%
0.1396
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$17.56
Offen:
$17.28
24-Stunden-Volumen:
190.22K
Relative Volume:
0.07
Marktkapitalisierung:
$2.27B
Einnahmen:
$745.97M
Nettoeinkommen (Verlust:
$-99.21M
KGV:
-22.90
EPS:
-0.7729
Netto-Cashflow:
$-5.09M
1W Leistung:
+1.67%
1M Leistung:
+6.76%
6M Leistung:
+98.32%
1J Leistung:
+125.06%
1-Tages-Spanne:
$17.15
$17.88
1-Wochen-Bereich:
$16.86
$17.90
52-Wochen-Spanne:
$7.065
$19.76
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, NTRA, IQV, IDXX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
17.70 | 2.26B | 745.97M | -99.21M | -5.09M | -0.7729 |
TMO
Thermo Fisher Scientific Inc
|
603.14 | 222.97B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.91 | 144.27B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
324.61 | 46.72B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
256.62 | 42.67B | 16.63B | 1.39B | 2.12B | 8.0674 |
IDXX
Idexx Laboratories Inc
|
518.37 | 40.98B | 4.45B | 1.10B | 1.06B | 13.59 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-29 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
NeoGenomics EVP Alicia Olivo Surrenders Shares for Tax Withholding Following Restricted Stock Vesting - Kalkine Media
Bank of New York Mellon Corp Takes Position in NeoGenomics, Inc. $NEO - MarketBeat
(NEO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Business Wire
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB) - The Globe and Mail
NeoGenomics Shares Rise After RaDaR ST Assay Gets Expanded Medicare Coverage - marketscreener.com
NeoGenomics Stock Just Turned Its First Profit, Creating an Optimal Entry Point - Barchart.com
NeoGenomics gains Medicare coverage for cancer MRD test By Investing.com - Investing.com Canada
NeoGenomics RaDaR ST wins expanded Medicare coverage for immunotherapy response monitoring - Bitget
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring - Yahoo Finance
NeoGenomics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Court Win Over Natera Patents Could Be A Game Changer For NeoGenomics’ (NEO) RaDaR ST - simplywall.st
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
NeoGenomics (NASDAQ:NEO) Healthcare Innovation Gains Attention - Kalkine Media
NeoGenomics (NASDAQ:NEO) Reaches New 12-Month HighHere's Why - MarketBeat
Neogenomics stock hits 52-week high at 16.93 USD By Investing.com - Investing.com Nigeria
Neogenomics stock hits 52-week high at 16.93 USD - Investing.com
NeoGenomics, Inc. Revenue Breakdown – NASDAQ:NEO - TradingView
NeoGenomics (NEO) Advances 1.44% to $16.17 as Buyers Hold Above Key SupportPercent Above MA - vinanet.vn
NeoGenomics (NASDAQ:NEO) Enters A New Growth Spotlight - Kalkine Media
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Neogenomics Stock Price Forecast. Should You Buy NEO? - StockInvest.us
NeoGenomics (NEO) stake tops 8% for First Light’s Mathew Arens - Stock Titan
NeoGenomics | SCHEDULE 13G/A: Others - Moomoo
California State Teachers Retirement System Raises Position in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics, Inc. (NEO) Stock Forecasts - Yahoo Finance
NeoGenomics Senior VP & Chief Accounting Officer Gregory Aunan Sells 80% Of Holding - simplywall.st
GC To Depart Cancer Diagnostic Co. NeoGenomics - Law360
Renaissance Technologies LLC Acquires New Shares in NeoGenomics, Inc. $NEO - MarketBeat
Form 8K NeoGenomics Inc For: 11 August By Investing.com - Investing.com India
Technical Reactions to NEO Trends in Macro Strategies - Stock Traders Daily
NeoGenomics announces planned departure of General Counsel Alicia Olivo - Investing.com
NeoGenomics (NEO) Slips to $16.50 as Biotech Diagnostic Stocks Face Cautious TradingVWAP Deviation - Vinanet
NeoGenomics (NASDAQ:NEO) Sets New 1-Year HighShould You Buy? - MarketBeat
MFG Wealth Management Inc. Takes Position in NeoGenomics, Inc. $NEO - marketbeat.com
NeoGenomics, Inc. (NEO) Stock forecasts - Yahoo Finance Australia
Has NeoGenomics (NEO) Priced In Its Turnaround Following Q2 Profitability? - simplywall.st
NeoGenomics (NEO) Is Up 8.4% After Q2 Profit Return And Raised 2026 Outlook – Has The Bull Case Changed? - finance.yahoo.com
Neogenomics stock hits 52-week high at 16.46 USD By Investing.com - Investing.com UK
Neogenomics stock hits 52-week high at 16.46 USD - Investing.com
NEOUSD (NEOUSD) Stock News Today - TradingKey
NeoGenomics Appoints Carolyn Starrett to its Board of Directors - The National Law Review
NeoGenomics, Inc. $NEO Stock Position Raised by Sei Investments Co. - MarketBeat
Dimensional Fund Advisors LP Buys 225,588 Shares of NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics, Inc. Revenue Breakdown – BX:NG9 - TradingView
NeoGenomics Laboratories Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Neogenomics Insider Sold Shares Worth $321,400, According to a Recent SEC Filing - marketscreener.com
NeoGenomics (NEO) accounting chief sells 20,000 shares, keeps equity awards - Stock Titan
BlackRock, Inc. Expands NeoGenomics Inc (NEO) Stake with Strategic Share Acquisition - GuruFocus
NeoGenomics Investor Alert - TMX Newsfile
NeoGenomics Shareholder Action Reminder - TMX Newsfile
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.07%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):